A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls
This is a multicentre, comparator-group, open-label, controlled, nonrandomised clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical diagnosis of PS (SDD; specifically, patients with PD [SDD], MSA [SDD] or PSP [SDD]) as compared with patients with a clinical diagnosis of ET (no SDD) and age-matched healthy controls.
• Assessment of DaTSCAN™ SPECT images by 3 independent blinded readers to compare specific striatal uptake with the clinical diagnosis.
• Central read (by semi-quantitative assessment by use of DaTQUANT™) of DaTSCANTM SPECT images to compare specific uptake with clinical diagnosis.
DaTSCAN™ Ioflupane (123I) Injection
Study Arms / Comparison Groups
DaTSCAN™ ioflupane (123I) injection
Description: Participants will receive a single intravenous (IV) injection of DaTSCAN™ (123I) ioflupane. Single photon emission computed tomography (SPECT) imaging will be performed between 3 to 6 hours post-injection and will last approximately 20 minutes to 1 hour.
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
June 18, 2020
December 16, 2021
Primary Completion Date
December 16, 2021
Inclusion Criteria: For all subjects: 1. Chinese male or female, aged 40 to 80 years, has agreed to sign and date the written informed consent form. For Healthy Volunteers: 2. Non-patient volunteers with good age-appropriate health as established by clinical examination during screening and no evidence of movement disorder by complete neurological evaluation. For patients with Parkinson's disease: 3. A diagnosis of clinically established or clinically probable PD in accordance with the MDS Clinical Diagnostic Criteria for Parkinson's Disease [Postuma et al. 2015]. For patients with MSA (SDD): 4. A diagnosis of probable or possible MSA in accordance with the Second Consensus Statement on the Diagnosis of MSA [Gilman et al. 2008]. For patients with PSP (SDD): 5. A diagnosis of probable or possible PSP in accordance with the Clinical Criteria for the Diagnosis of Progressive Supranuclear Palsy National Institute for Neurological Disorders and Society for PSP (NINDS-SPSP) [Litvan et al. 1996]. For patients with ET (no SDD): 6. A diagnosis of definite or probable ET in accordance with the Washington Heights-Inwood Genetic Study of Essential Tremor (WHIGET) diagnostic criteria for ET (no SDD) [Louis et al. 1997]. Exclusion Criteria: 1. The subject is lactating. 2. The subject is pregnant as detected by a β-human chorionic gonadotropin (β-hCG) pregnancy test. 3. A cerebral structural vascular abnormality indicative of at least 1 infarction in the region of the basal ganglia (including the internal capsule) ≥5 mm has been confirmed, preferably by magnetic resonance imaging (MRI) performed within 6 months of screening. If an MRI is not clinically feasible, cerebral CT imaging within 6 months is also acceptable. 4. The subject is diagnosed with major neurocognitive disorder by the Diagnostic and Statistical Manual of Mental Disorders (DSM) 5 criteria, or Mini-Mental State Examination total score is <24. 5. Subject is being investigated for or has been diagnosed and/or is being treated for repeated stroke with stepwise progression of Parkinson features. 6. History of repeated head injury (≥3 concussions, or history of professional sports with repeated head trauma [e.g., boxing]). 7. History of definite encephalitis (≥1 episode of confirmed encephalitis with objective residual neurologic deficit). 8. The subject is using or has insufficient washout from medication known or suspected to interact with striatal uptake through direct competition with binding of DaTSCAN™ to the dopamine transporters (i.e., amphetamine, benztropine, bupropion, cocaine, mazindol, methylphenidate, phentermine, sertraline, selective serotonin reuptake inhibitors) before the imaging visit. 9. The patient is using Chinese traditional medicine for PD treatment, which cannot be safely withdrawn for at least 1 week (7 days) before the imaging visit. 10. The subject has a moderate to severe renal impairment (e.g., serum creatinine >1.5x upper limit of normal [ULN], blood urea nitrogen [BUN] >30 mg/dL). 11. The subject has a moderate to severe hepatic impairment (bilirubin >2x ULN and alanine aminotransferase (ALT) or aspartate aminotransferase (AST)>3x ULN). 12. The subject has a history of current abuse of drugs and/or alcohol (for the previous 12 months before trial enrolment). 13. The subject has a history of occupational exposure to any radiation >50 mSv/year. 14. The subject has been previously enrolled in this study or participated in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening and/or any radiopharmaceutical within a minimum of 5 radioactive half-lives prior to screening. 15. The subject presents with symptoms suggestive of corticobasal degeneration or Huntington's disease. 16. The subject has known allergies to the investigational medicinal product (IMP). 17. The subject presents with any clinically active, serious, life-threatening disease with a life expectancy of less than 12 months. 18. Any laboratory value(s) exceeding the limits of normality if deemed to be clinically relevant by the investigator. 19. The subject complains of claustrophobia. 20. The subject has a moderate to severe thyroid disease (thyroid stimulating hormone [TSH] exceeding the limits of normality by more than 10%), if deemed to be clinically relevant by the investigator. For patients with ET: 21. The patient has at least 1 first-degree relative diagnosed with PD. For Healthy Volunteers: 22. History of psychiatric illness. For all subjects: 23. It is the physician's best judgment not to include the patient in the trial.
40 Years - 80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers